Synthesis of (E)-8-(3-chlorostyryl)caffeine analogues leading to 9-deazaxanthine derivatives as dual A2A antagonists/MAO-B inhibitors

Journal of Medicinal Chemistry

Volumn 56, Issue 3, 2013, Pages 1247-1261

  Rivara, Silvia ^a   Piersanti, Giovanni ^b   Bartoccini, Francesca ^b   Diamantini, Giuseppe ^b   Pala, Daniele ^a   Riccioni, Teresa ^c   Stasi, Maria Antonietta ^c   Cabri, Walter ^c   Borsini, Franco ^c   Mor, Marco ^a   Tarzia, Giorgio ^b   Minetti, Patrizia ^c  

^a UNIVERSITY OF PARMA   (Italy)

^b UNIVERSITY OF URBINO   (Italy)

^c Sigma Tau SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE DERIVATIVE; HALOPERIDOL; MONOAMINE OXIDASE B INHIBITOR;

ARTICLE; CATALEPSY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; IC 50; STRUCTURE ACTIVITY RELATION;

CAFFEINE; HEK293 CELLS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; MONOAMINE OXIDASE INHIBITORS; XANTHINES;

EID: 84873937179     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm301686s     Document Type: Article

References (88)

1. Rampa, A.; Belluti, F.; Gobbi, S.; Bisi, A. Hybrid-Based Multitarget Ligands for the Treatment of Alzheimer's Disease Curr. Top. Med. Chem. 2011, 11, 2716-2730
2. Van der Schyf, C. J.; Geldenhuys, W. J. Multimodal Drugs and their Future for Alzheimer's and Parkinson's Disease Int. Rev. Neurobiol. 2011, 100, 107-125
3. Geldenhuys, W. J.; Youdim, M. B.; Carroll, R. T.; Van der Schyf, C. J. The Emergence of Designed Multiple Ligands for Neurodegenerative Disorders Prog. Neurobiol. 2011, 94, 347-359
4. Jacobson, K. A.; Gallo-Rodriguez, C.; Melman, N.; Fischer, B.; Maillard, M.; van Bergen, A.; van Galen, P. J.; Karton, Y. Structure-Activity Relationships of 8-Styrylxanthines as A2-Selective Adenosine Antagonists J. Med. Chem. 1993, 36, 1333-1342
5. Shimada, J.; Koike, N.; Nonaka, H.; Shiozaki, S.; Yanagawa, K.; Kanda, T.; Kobayashi, H.; Ichimura, M.; Nakamura, J.; Kase, H.; Suzuki, F. Adenosine A2A Antagonists with Potent Anticataleptic Activity Bioorg. Med. Chem. Lett. 1997, 7, 2349-2352
6. Shiozaki, S.; Ichikawa, S.; Nakamura, J.; Kitamura, S.; Yamada, K.; Kuwana, Y. Actions of Adenosine A2A Receptor Antagonist KW 6002 on Drug-Induced Catalepsy and Hypokinesia Caused by Reserpine or MPTP Psychopharmacology 1999, 147, 90-95
7. Kase, H. The adenosine A2A receptor selective antagonist KW6002: Research toward a novel non-dopaminergic therapy for Parkinson's disease Neurology 2003, 61, S97-S100
8. Shimada, J.; Suzuki, F.; Nonaka, H.; Ishii, A.; Ichikawa, S. (E)-1,3-Dialkyl-7-methyl-8-(3,4,5-trimethoxystyryl)xanthines: Potent and Selective Adenosine A2 Antagonists J. Med. Chem. 1992, 35, 2342-2345
9. Nonaka, Y.; Shimada, J.; Nonaka, H.; Koike, N.; Aoki, N.; Kobayashi, H.; Kase, H.; Yamaguchi, K.; Suzuki, F. Photoisomerization of a Potent and Selective Adenosine A2 Antagonist, (E)-1,3-Dipropyl-8-(3,4-dimethoxystyryl)-7- methylxanthine J. Med. Chem. 1993, 36, 3731-3733
10. Suzuki, F.; Shimada, J.; Ishii, A.; Nonaka, H.; Kosaka, N.; Ichikawa, S. Xanthine Derivatives. PCT Patent WO 92/06976, 1992.
11. Correa, M.; Wisniecki, A.; Betz, A.; Dobson, D. R.; O'Neill, M. F.; O'Neill, M. J.; Salamone, J. D. The adenosine A2A antagonist KF17837 reverses the locomotor suppression and tremulous jaw movements induced by haloperidol in rats: possible relevance to parkinsonism Behav. Brain Res. 2004, 148, 47-54
12. Seale, T. W.; Abla, K. A.; Shamim, M. T.; Carney, J. M.; Daly, J. W. 3,7-Dimethyl-1-propargylxanthine: a potent and selective in vivo antagonist of adenosine analogs Life Sci. 1988, 43, 1671-1684
13. Müller, C. E.; Geis, U.; Hipp, J.; Schobert, U.; Frobenius, W.; Pawłowski, M.; Suzuki, F.; Sandoval-Ramìrez, J. Synthesis and structure-activity relationships of 3,7-dimethyl-1-propargylxanthine derivatives, A2A-selective adenosine receptor antagonists J. Med. Chem. 1997, 40, 4396-4405
14. Sauer, R.; Maurinsh, J.; Reith, U.; Fülle, F.; Klotz, K.-N.; Müller, C. E. Water soluble phosphate prodrugs of 1-propargyl-8- styrylxanthine derivatives, A2A selective adenosine receptor antagonists J. Med. Chem. 2000, 43, 440-448
15. Hockemeyer, J.; Burbiel, J. C.; Muller, C. E. Multigram-scale syntheses, stability, and photoreactions of A2A adenosine receptor antagonists with 8-styrylxanthine structure: potential drugs for Parkinson's disease J. Org. Chem. 2004, 69, 3308-3318
16. Vollmann, K.; Qurishi, R.; Hockemeyer, J.; Muller, C. E.. Synthesis and properties of a new water-soluble prodrug of the adenosine A2A receptor antagonist MSX-2 Molecules 2008, 13, 348-359
17. Yang, M.; Soohoo, D.; Soelaiman, S.; Kalla, R.; Zablocki, J.; Chu, N.; Leung, K.; Yao, L.; Diamond, I.; Belardinelli, L.; Shryock, J. C. Characterization of the potency, selectivity, and pharmacokinetic profile for six adenosine A2A receptor antagonists Naunyn Schmiedeberg's Arch. Pharmacol. 2007, 375, 133-144
18. Baraldi, P. G.; Manfredini, S.; Simoni, D.; Zappaterra, L.; Zocchi, C.; Dionisotti, S.; Ongini, E. Synthesis of New Pyrazolo-[4,3- e ]1,2,4-triazolo[1,5- c ]pyrimidine and 1,2,3-triazolo[4,5- e ]1,2,4-triazolo[1,5- c ]pyrimidine Displaying Potent and Selective Activity as A2A Adenosine Receptor Antagonists Bioorg. Med. Chem. Lett. 1994, 4, 2539-2544
19. Zocchi, C.; Ongini, E.; Conti, A.; Monopoli, A.; Negretti, A.; Baraldi, P. G.; Dionisotti, S. The Non-Xanthine Heterocyclic Compound SCH 58261 is a New Potent and Selective A2A Adenosine Receptor Antagonist J. Pharmacol. Exp. Ther. 1996, 276, 398-404
20. Ongini, E. SCH58261: a Selective A2A Adenosine Receptor Antagonist Drug. Dev. Res. 1997, 42, 63-70
21. Baraldi, P. G.; Fruttarolo, F.; Tabrizi, M. A.; Preti, D.; Romagnoli, R.; El-Kashef, H.; Moorman, A.; Varani, K.; Gessi, S.; Merighi, S.; Borea, P. A. Design, Synthesis, and Biological Evaluation of C9- and C2-Substituted Pyrazolo[4,3- e ]-1,2,4-triazolo[1,5- c ]pyrimidines as New A2A and A3 Adenosine Receptors Antagonists J. Med. Chem. 2003, 46, 1229-1241
22. Caulkett, P. W. R.; Jones, G.; McPartlin, M.; Renshaw, N. D.; Stewart, S. K.; Wright, B. Adenine Isosteres with Bridgehead Nitrogen. Part 1. Two Independent Synthesis of the [1,2,4]-triazolo[1,5- a ][1,3,5]triazine Ring System Leading to a Range of Substituents in the 2, 5 and 7 Positions J. Chem. Soc., Perkin Trans. 1 1995, 7, 801-808
23. Poucher, S. M.; Keddie, J. R.; Singh, P.; Stoggall, S. M.; Caulkett, P. W. R.; Jones, G.; Collis, M. G. The in vitro pharmacology of ZM 241385, a Potent, Non-Xanthine, A2A Selective Adenosine Receptor Antagonist Br. J. Pharmacol. 1995, 115, 1096-1102
24. Francis, J. E.; Cash, W. D.; Psychoyos, S.; Ghai, G.; Wenk, P.; Friedmann, R. C.; Atkins, C.; Warren, V.; Furness, P.; Hyun, J. L.; Stone, G. A.; Desai, M.; Williams, M. Structure-Activity Profile of a Series of Novel Triazoloquinazoline Adenosine Antagonists J. Med. Chem. 1988, 31, 1014-1020
25. Minetti, P.; Tinti, M. O.; Carminati, P.; Castorina, M.; Di Cesare, M.-A.; Di Serio, S.; Gallo, G.; Ghirardi, O.; Giorgi, F.; Giorgi, L.; Piersanti, G.; Bartoccini, F.; Tarzia, G. 2- n -Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9 H -purin-6-ylamine and Analogues as A2A Adenosine Receptor Antagonists. Design, Synthesis, and Pharmacological Characterization J. Med. Chem. 2005, 48, 6887-6896
26. Bartoccini, F.; Cabri, W.; Celona, D.; Minetti, P.; Piersanti, G.; Tarzia, G. Direct B-Alkyl Suzuki-Miyaura Cross-Coupling of 2-Halopurines. Practical Synthesis of ST1535, a Potent Adenosine A2A Receptor Antagonist J. Org. Chem. 2010, 75, 5398-5401
27. Rose, S.; Jackson, M. J.; Smith, L. A.; Stockwell, K.; Johnson, L.; Carminati, P.; Jenner, P. The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets Eur. J. Pharmacol. 2006, 546, 82-87
28. Tozzi, A.; Tscherter, A.; Belcastro, V.; Tantucci, M.; Costa, C.; Picconi, B.; Centonze, D.; Calabresi, P.; Borsini, F. Interaction of A2A adenosine and D2 dopamine receptors modulates corticostriatal glutamatergic transmission Neuropharmacology 2007, 53, 783-789
29. Tronci, E.; Simola, N.; Borsini, F.; Schintu, N.; Fraura, L.; Carminati, P.; Morelli, M. Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats Eur. J. Pharmacol. 2000, 566, 94-102
30. Rose, S.; Ramsay Croft, N.; Jenner, P. The novel adenosine A2a antagonist ST1535 potentiates the effects of a threshold dose of L-dopa in unilaterally 6-OHDA-lesioned rats Brain Res. 2007, 1133, 110-114
31. Pinna, A.; Pontis, S.; Borsini, F.; Morelli, M. Adenosine A2A Receptor Antagonists Improve Deficits in Initiation of Movement and Sensory Motor Integration in the Unilateral 6-Hydroxydopamine Rat Model of Parkinson's Disease Synapse 2007, 61, 606-614
32. Galluzzo, M.; Pintor, A.; Pèzzola, A.; Grieco, R.; Borsini, F.; Popoli, P. Behavioural and neurochemical characterization of the adenosine A2A receptor antagonist ST1535 Eur. J. Pharmacol. 2008, 579, 149-152
33. Belcastro, V.; Tozzi, A.; Tantucci, M.; Costa, C.; Di Filippo, M.; Autuori, A.; Picconi, B.; Siliquini, S.; Luchetti, E.; Borsini, F.; Calabresi, P. A2A adenosine receptor antagonists protect the striatum against rotenone-induced neurotoxicity Exp. Neurol. 2009, 217, 231-234
34. Frau, L.; Borsini, F.; Wardas, J.; Khairnar, A.; Scjintu, N.; Morelli, M. Neuroprotective and Anti-inflammatory Effects of the Adenosine A2A Receptor Antagonist ST1535 in a MPTP Mouse Model of Parkinson's Disease Synapse 2011, 65, 181-188
35. Park, A.; Stacy, M. Isradefillyne for the treatment of Parkinson's disease Expert Opin. Pharmacother. 2012, 13, 111-114
36. Gaines, K. D.; Hinson, V. K. Adjunctive Therapy in Parkinson's Disease: The Role of Rasagiline Neuropsychiatr. Dis. Treat. 2012, 8, 285-294
37. Rascol, O.; Fitzer-Attas, C. J.; Hauser, R.; Jankovic, J.; Lang, A.; Langston, J. W.; Melamed, E.; Poewe, W.; Stocchi, F.; Tolosa, E.; Eyal, E.; Weiss, Y. M.; Olanow, C. W. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): pre-specified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes Lancet Neurol. 2011, 10, 415-423
38. Magyar, K.; Szende, B.; Jenei., V.; Tábi, T.; Pálfi, M.; Szökö, é. (R)-Deprenyl: Pharmacological Spectrum of its Activity Neurochem. Res. 2010, 35, 1922-1932
39. Nicotra, A.; Pierucci, F.; Parvez, H.; Santori, O. Monoamine oxidase expression during development and aging Neurotoxicology 2004, 25, 155-165
40. Fowler, J. S; Volkow, N. D.; Wang, G.-J.; Logan, J.; Pappas, N.; Shea, C.; MacGregor, R. Age-related increases in brain monoamine oxidase B in living healthy human subjects Neurobiol. Aging 1997, 18, 431-435
41. Saura, J.; Beurl, Z.; Ulrich, J.; Mendelowitsch, A.; Chen, K.; Shih, J. C.; Malherbe, P.; Da Prada, M.; Richards, J. G. Molecular Neuroanathomy of Human Monoamine oxidases A and B Revealed by Quantitative Enzyme Radioautography and in Situ Hybridization Histochemistry Neuroscience 1996, 70, 755-774
42. Chen, J.; Steyn, S.; Staal, R.; Petzer, J. P.; Kui, X.; van der Schyf, C. J.; Castagnoli, K.; Sonsalla, P. K.; Castagnoli, N., Jr.; Schwarzschild, M. A. 8-(3-Chlorostyryl)caffeine May Attenuate MPTP Neurotoxicity through Dual Actions of Monoamine Oxidase Inhibition and A2A Receptor Antagonism J. Biol. Chem. 2002, 277, 36040-36044
43. Petzer, J. P.; Steyn, S.; Castagnoli, K. P.; Chen, J. F.; Schwarzschild, M. A.; Van der Schyf, C. J.; Castagnoli, N. Inhibition of Monoamine Oxidase B by Selective Adenosine A2A Receptor Antagonists Bioorg. Med. Chem. 2003, 11, 1299-1310
44. van den Berg, D.; Zoellner, K. R.; Ogunrombi, M. O.; Malan, S. F.; Terre'Blanche, G.; Castagnoli, N.; Bergh, J. J., Jr.; Petzer, J. P. Inhibition of Monoamine Oxidase B by Selected Benzimidazole and Caffeine Analogues Bioorg. Med. Chem. 2007, 15, 3692-3702
45. Kui, X.; Bastia, E.; Schwarzschild, M. Therapeutic potential of adenosine A2A receptor antagonists in Parkinson's disease Pharmacol. Ther. 2005, 105, 267-310
46. Schwarzschild, M. A.; Agnati, L.; Fuxe, K.; Chen, J. F.; Morelli, M. Targeting adenosine A2A receptors in Parkinson's disease Trends Neurosci. 2006, 29, 647-654
47. Vlok, N.; Malan, S. F.; Castagnoli, N., Jr.; Bergh, J. J.; Petzer, J. P. Inhibition of monoamine oxidase B by analogues of the adenosine A2A receptor antagonist (E)-8-(3-chlorostyryl)caffeine (CSC) Bioorg. Med. Chem. 2006, 14, 3512-3521
48. Pretorius, J.; Malan, S. F.; Castagnoli, N., Jr.; Bergh, J. J.; Petzer, J. P. Dual inhibition of monoamine oxidase B and antagonism of the adenosine A2A receptor by (E, E)-8-(4-phenylbutadien-1-yl)caffeine analogues Bioorg. Med. Chem. 2008, 16, 8676-8684
49. Petzer, J. P.; Castagnoli, N., Jr.; Schwarzschild, M. A.; Chen, J.-F.; van der Schyf, C. J. Dual-Target-Directed Drugs that Block Monoamine Oxidase B and Adenosine A2A Receptors for Parkinson's Disease Neurotherapeutics 2009, 6, 141-151
50. Armentero, M. T.; Pinna, A.; Ferré, S.; Lanciego, J. L.; Müller, C. E.; Franco, R. Past, present and future of A2A adenosine receptor antagonists in the therapy of Parkinson's disease Pharmacol. Ther. 2011, 132, 280-299
51. Pisani, L.; Catto, M.; Leonetti, F.; Nicolotti, O.; Stefanachi, A.; Campagna, F.; Carotti, A. Targeting Monoamine Oxidases with Multipotent Ligands: An Emerging Strategy in the Search of New Drugs Against Neurodegenerative Diseases Curr. Med. Chem. 2011, 18, 4568-4587
52. Aguiar, L. M.; Maceîdo, D. S.; Vasconcelos, S. M.; Oliveira, A. A.; de Sousa, F. C.; Viana, G. S. CSC, an adenosine A(2A) receptor antagonist and MAO B inhibitor, reverses behavior, monoamine neurotransmission, and amino acid alterations in the 6-OHDA-lesioned rats Brain Res. 2008, 1191, 192-199
53. Collins, C. J.; Bupp, J. E.; Tanga, M. J. Synthesis of 2-amino-1-methyl-6-phenylimidazo[4,5- b ]pyridine (PhIP), a heterocyclic food mutagen ARKIVOC 2002, 90-96
54. Wang, T.-C.; Chen, Y.-L.; Lee, K.-H.; Tzeng, C.-C. Lewis Acid Catalyzed Reaction of Cinnamanilides: Competition of Intramolecular and Intermolecular Friedel-Crafts Reaction Synthesis 1997, 87-90
55. Crey-Desbiolles, C.; Lhomme, J.; Dumy, P.; Kotera, M. 3-Nitro-3-deaza-2′-deoxyadenosine as a Versatile Photocleavable 2′-Deoxyadenosine Mimic J. Am. Chem. Soc. 2004, 126, 9532-9533
56. Konno, K.; Hashimoto, K.; Shirahama, H.; Matsumoto, T. Improved Procedures for Preparation of 2-Pyridones and 2-Hydroxymethylpyridines from Pyridine N -Oxides Heterocycles 1986, 24, 2169-2172
57. Majumdar, K. C. Mukhopadhyay C-C Bond Formation by Radical Cyclization: Synthesis of Pyrimidine-Annulated Heterocycles Synthesis 2003, 6, 920-924
58. Kataoka, N.; Shelby, Q.; Stambuli, J. P.; Hartwing, J. F. Air Stable, Sterically Hindered Ferrocenyl Dialkylphosphines for Palladium-Catalyzed C-C, C-N, and C-O Bond-Forming Cross-Couplings J. Org. Chem. 2002, 67, 5553-5566
59. Pawar, S. S.; Shingare, M. S.; Thore, S. N. A Novel Approach for Ligand Promoted Palladium (II)-Catalyzed Suzuki Coupling of Aryl Iodides and Bromides with Arylboronic Acid in Aqueous Media Lett. Org. Chem. 2007, 4, 486-490
60. Bartoccini, F.; Piersanti, G.; Mor, M.; Tarzia, G.; Minetti, P.; Cabri, W. Divergent Synthesis of Novel 9-Deazaxanthine Derivatives via Late-Stage Cross-Coupling Reactions Org. Biomol. Chem. 2012, 10, 8860-8867
61. Torborg, C.; Beller, M. Recent Applications of Palladium-Catalyzed Coupling Reactions in the Pharmaceutical, Agrochemical, and Fine Chemical Industries Adv. Synth. Catal. 2009, 351, 3027-3043
62. Surry, D. S.; Buchwald, S. L. Biaryl Phosphane Ligands in Palladium-Catalyzed Amination Angew. Chem., Int. Ed. 2008, 47, 6338-6361
63. Hartwig, J. F. Evolution of a Fourth Generation Catalyst for the Amination and Thioetherification of Aryl Halides Acc. Chem. Res. 2008, 41, 1534-1544
64. Klapars, A.; Buchwald, S. L. Copper-Catalyzed Halogen Exchange in Aryl Halides: An Aromatic Finkelstein Reaction J. Am. Chem. Soc. 2002, 124, 14844-14845
65. Humphreys, J. L.; Lowes, D. J.; Wesson, K. A.; Whitehead, R. C. Arene cis -dihydrodiols-useful precursors for the preparation of antimetabolites of the shikimic acid pathway: application to the synthesis of 6,6-difluoroshikimic acid and (6 S)-6-fluoroshikimic acid Tetrahedron 2006, 62, 5099-5108
66. Bistri, O.; Correa, A.; Bolm, C. Iron-Catalyzed C-O Cross-Couplings of Phenols with Aryl Iodides Angew. Chem., Int. Ed. 2008, 47, 586-588
67. Xia, N.; Taillefer, M. Copper- or Iron-Catalyzed Arylation of Phenols from respectively Aryl Chlorides and Aryl Iodides Chem.-Eur. J. 2008, 14, 6037-6039
68. Buchwald, S. L.; Bolm, C. Copper-Catalyzed Cross-Couplings with Parts-per-Million Catalyst Loadings Angew. Chem., Int. Ed. 2009, 48, 5691-5693
69. Buchwald, S. L.; Bolm, C. On the Role of Metal Contaminants in Catalyses with FeCl3 Angew. Chem., Int. Ed. 2009, 48, 5586-5587
70. Andersen, J.; Bolvig, S.; Liang, X. Efficient One-Pot Synthesis of 1-Aryl 1,2,3-Triazoles from Aryl Halides and Terminal Alkynes in the Presence of Sodium Azide Synlett 2005, 2941-2947
71. Donghee, K.; Sungwoo, H. Palladium(II)-Catalyzed Direct Intermolecular Alkenylation of Chromones Org. Lett. 2011, 13, 4466-4469
72. During the preparation of our manuscript, was reported a slightly different dehydrogenative Heck coupling for the preparation of alkenylated xanthine, see Huang, Y.; Song, F.; Wang, Z.; Xi, P.; Wu, N.; Wang, Z.; Lan, J.; You, J. Dehydrogenative Heck coupling of biologically relevant N -heteroarenes with alkenes: discovery of fluorescent core frameworks Chem. Commun. 2012, 48, 2864-2866
73. Grahner, B.; Winiwarter, S.; Lanzner, W.; Müller, C. E. Synthesis and structure-activity relationships of deazaxanthines: analogs of potent A1- and A2-adenosine receptor antagonists J. Med. Chem. 1994, 37, 1526-1534
74. Doré, A. S.; Robertson, N.; Errey, J. C.; Ng, I.; Hollenstein, K.; Tehan, B.; Hurrell, E.; Bennett, K.; Congreve, M.; Magnani, F.; Tate, C. G.; Weir, M.; Marshall, F. H. Structure of the adenosine A(2A) receptor in complex with ZM241385 and the xanthines XAC and caffeine Structure 2011, 19, 1283-1293
75. Liu, W.; Chun, E.; Thompson, A. A.; Chubukov, P.; Xu, F.; Katritch, V.; Han, G. W.; Roth, C. B.; Heitman, L. H.; IJzerman, A. P.; Cherezov, V.; Stevens, R. C. Structural basis for allosteric regulation of GPCRs by sodium ions Science 2012, 337, 232-236
76. Glide, version 5.7; Schrödinger, LLC: New York, 2011.
77. Strydom, B.; Malan, S. F.; Castagnoli, N., Jr.; Bergh, J. J.; Petzer, J. P. Inhibition of monoamine oxidase by 8-benzyloxycaffeine analogues Bioorg. Med. Chem. 2010, 18, 1018-1028
78. Binda, C.; Wang, J.; Pisani, L.; Caccia, C.; Carotti, A.; Salvati, P.; Edmondson, D. E.; Mattevi, A. Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs J. Med. Chem. 2007, 50, 5848-5852
79. Müller, C. E.; Schobert, U.; Hipp, J.; Geis, U.; Frobenius, W.; Pawlowski, M. Configurationally stable analogs of styrylxanthines as A2A adenosine receptor antagonists Eur. J. Med. Chem. 1997, 32, 709-719
80. Caccia, C.; Maj, R.; Calabresi, M.; Maestroni, S.; Faravelli, L.; Curatolo, L.; Salvati, P.; Fariello, R. G. Safinamide: from molecular targets to a new anti-Parkinson drug Neurology 2006, 67, S18-S23
81. Tests performed by Cerep. For experimental details, see http://www.cerep.fr/cerep/users/pages/catalog/assay/catalog.asp.
82. Trevitt, J.; Kawa, K.; Jalali, A.; Larsen., C. Differential effects of adenosine antagonists in two models of parkinsonian tremor Pharmacol., Biochem. Behav. 2009, 94, 24-29
83. Cheng, Y. C.; Prusoff, W. H. Deoxyribonucleotide Metabolism in Herpes Simplex Virus Infected HeLa Cells Biochem. Pharmacol. 1973, 22, 3099-3108
84. Maestro, version 9.2; Schrödinger, LLC: New York, 2011.
85. MacroModel, version 9.9; Schrödinger, LLC: New York, 2011.
86. Halgren, T. A. MMFF VII. Characterization of MMFF94, MMFF94s, and other widely available force fields for conformational energies and for intermolecular-interaction energies and geometries J. Comput. Chem. 1999, 20, 730-748
87. Prime, version 3.0; Schrödinger, LLC: New York, 2011.
88. Kaminski, G. A.; Friesner, R. A.; Tirado-Rives, J.; Jorgensen, W. L. Evaluation and reparametrization of the OPLS-AA force field for proteins via comparison with accurate quantum chemical calculations on peptides J. Phys. Chem. B 2001, 105, 6474-6487